Ascletis Pharma Inc. announces late-breaking abstract poster presentation of interim results from Phase IIb expansion cohort of ASC22 for functional cure of chronic hepatitis B, and abstract poster presentation of Phase I study results of ASC41 for treatment of non-alcoholic steatohepatitis at The Liver Meeting® 2023 of the American Association for the Study of Liver Diseases.
